Exyte Completes TTP Acquisition
Deal News | Nov 05, 2024 | PR Newswire Cision Exyte
Exyte, a global leader in designing and delivering high-tech facilities, has completed the acquisition of TTP Group, a leading European engineering firm specializing in biotech and pharmaceutical industries. The deal, announced in September 2024, received the necessary regulatory approvals. TTP, an established partner for biotech and pharma companies, operates in Europe through its brands Pharmaplan and Triplan. This acquisition aligns with Exyte's "Next Level" strategy and enhances its biopharma and life sciences sectors in Europe. TTP's engineering expertise complements Exyte's capabilities, offering strengthened support in Europe's growing pharma market. The acquisition supports Exyte's strategic expansion, increasing its sales targets for its Biopharma and Life Sciences unit.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- Europe – The operations and strategic expansion discussed in the article focus on Europe, highlighting its importance in both TTP and Exyte's business strategy.
- Germany – Exyte's headquarters are located in Stuttgart, Germany, and the acquisition impacts the German market.
Industry
- Biotechnology – The article discusses the acquisition of TTP Group, which specializes in biotech, indicating a potential influence on the biotechnology industry.
- Pharmaceuticals – The acquisition enhances Exyte's operations in the pharmaceutical industry, showing its significance for pharmaceutical facility engineering and development.
Financials
- €580 million – Revenue of Exyte's Biopharma and Life Sciences segment in 2023.
- €650 million – Order intake for Exyte's Biopharma and Life Sciences segment, indicating growth.
- €1.5 billion – Projected medium-term sales target for Exyte's Biopharma and Life Sciences business.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Exyte | Acquirer | Company | A global leader in designing, engineering, and delivering high-tech facilities for industries, including biotechnology and pharmaceuticals. |
| TTP Group | Target Company | Company | A leading engineering firm specializing in biotech and pharmaceutical sectors across Europe, operating under the brands Pharmaplan and Triplan. |
| Dr. Wolfgang Büchele | CEO | Person | The CEO of Exyte, who highlighted the strategic value of the TTP acquisition. |
| Dr. Andreas Bonhoff | CEO | Person | CEO of TTP Group, expressed the growth prospects of the acquisition. |
| Ronan Donohue | President of Biopharma and Life Sciences Global Business Unit | Person | Oversees the Biopharma and Life Sciences unit, key to Exyte's operations. |